The latest from CDMOs, CMOs, and suppliers featuring Euroapi & SK pharmteco.  

Chemicals/Chemical API Manufacturing
* Euroapi Names New Chair & CEO 
General 
* SK pharmteco Consolidates Brands into One Company

---

Chemicals/Chemical API Manufacturing

Euroapi Names New Chair & CEO 
Euroapi, a supplier and CMDO of active pharmaceutical ingredients (APIs) that was previously spun off from Sanofi in 2022, has appointed Emmanuel Blin, a member of the company’s Board as its new Chair, and David Seignolle, formerly the company’s Chief Operating Officer, as its new Chief Executive Officer (CEO), effective December 9, 2024. They respectively succeed Viviane Monges as Director and Chair of the Board and Ludwig de Mot as CEO, both who have resigned from the company. 

The leadership changes come amidst a restructuring of the company, dubbed Focus 27, which is aimed at improving the company’s financial performance. Euroapi has two main business activities. It is a supplier of APIs, with a portfolio of approximately 200 APIs, which in 2023, accounted for 72% of the company’s net sales, and a CDMO business, which accounted for the remaining 28% of the company’s 2023 net sales. Its restructuring plan involves four main elements: streamlining its API portfolio to more value-added products, increasing the revenue share of its CDMO business, consolidating its manufacturing footprint, and reducing headcount. 

Blin has been a member of the company’s board since May 2022. He is the founder and CEO of Tech Care for All (TC4A), a social impact company aiming to accelerate digital health in Africa and Asia, which was created in 2017. Previously, he spent 20 years in the pharmaceutical industry. He is a former member of the Executive Committee of Bristol-Myers Squibb, where he was Chief Strategy Officer and Co-Commercialization Director, after a series of assignments leading national and regional operations in Europe, Asia, and the Americas.  

Prior to his role as COO of Euroapi, Seignolle served as Expert Partner in the Healthcare Practice of Bain & Company. Prior to that, he spent six years at Teva, where he held several leadership positions, including Head of Operations for Teva API in Italy and Mexico and Vice President, Global Supply Chain, API and Biologics. He has also served five years at McKinsey & Company in France and in the US, where he was focused on pharma operations after beginning his career in procurement at Toyota Motor Europe. 

Source: Euroapi 

---

General 

SK pharmteco Consolidates Brands into One Company 
SK pharmteco, a CDMO of small-molecule active pharmaceutical ingredients and cell and gene therapies, has announced the launch of a brand unification initiative.  

The move brings together the capabilities of SK biotek, SK biotek Ireland, the Center for Breakthrough Medicines, Yposkesi, Ampac Fine Chemicals, and Ampac Analytical to create a single CDMO. While these individual brands will continue to operate, they will now be known collectively as SK pharmteco. 

The unified SK pharmteco has a global footprint with facilities across North America, Europe, and Asia. The company’s expanded service portfolio encompasses process development and manufacture of small molecules (APIs intermediates and regulatory starting materials), cell- and gene-therapy development and manufacturing, and analytical development and testing services. 

Source: SK pharmteco